Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511562 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
A Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
- 20
- Study locations
NCT01511562 is a Phase 2 study of Lymphoma that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 113 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT01511562, a Phase 2 study of Lymphoma, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma. Currently the best treatment for patients with primary CNS B-cell lymphoma is not known.
Conditions Studied
Interventions
- DRUG etoposide
- DRUG carmustine
- DRUG cytarabine
- DRUG thiotepa
- PROCEDURE stem cell transplant
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- UC San Diego Moores Cancer Center - La Jolla
- University of California Davis Comprehensive Cancer Center - Sacramento
- UCSF Medical Center-Mount Zion - San Francisco
- UCSF Medical Center-Parnassus - San Francisco
Idaho
- Saint Luke's Mountain States Tumor Institute - Boise
- Saint Luke's Mountain States Tumor Institute - Fruitland - Fruitland
- Saint Luke's Mountain States Tumor Institute - Meridian - Meridian
- Saint Luke's Mountain States Tumor Institute - Nampa - Nampa
Connecticut
- Yale University - New Haven
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2012-09 |
| Est. Completion | 2027-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01511562
The ClinicalTrials.gov registry entry for NCT01511562 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (77% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which etoposide is the first listed.
NCT01511562 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Alaska, California, Idaho.
Frequently Asked Questions
What is clinical trial NCT01511562 about?
NCT01511562 is a clinical study titled "Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma". The purpose of this study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma. Currently the best treatment for patients with primary CNS B-cell lymphoma is not known.
What is the current status of trial NCT01511562?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2012-09. Estimated completion is 2027-05-02.
What conditions does trial NCT01511562 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT01511562?
The interventions under investigation include: etoposide (DRUG), carmustine (DRUG), cytarabine (DRUG), thiotepa (DRUG), stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT01511562?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01511562 being conducted?
This trial has 20 study locations across Alaska, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.